NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective November 13, 2017, NewLink Genetics Corporation (the "Company") has appointed Eugene P. “Gene” Kennedy, age 49, as Chief Medical Officer of the Company.
Dr. Kennedy joined NewLink in 2014 from Thomas Jefferson University in Philadelphia, PA where he served from 2006 to 2013, progressing to the rank of Associate Professor of Surgery and held leadership positions including Chief of the Section of Pancreaticobiliary Surgery and Co-Director of the Jefferson Pancreas, Biliary, and Related Cancers Center. Previously, Dr. Kennedy has held faculty positions at the Johns Hopkins Hospital in Baltimore, MD from 2004 to 2005 and the Louisiana State University School of Medicine in New Orleans, LA in 2005. Dr. Kennedy obtained his undergraduate education at the University of Virginia and received his medical degree from the Medical College of Virginia. He completed a residency and fellowship in Surgery and Surgical Oncology as well as a research fellowship in tumor immunology at the Johns Hopkins Hospital.
There are no family relationships between Dr. Kennedy and any director or executive officer of the Company. There are no transactions in which Dr. Kennedy has an interest that are required to be disclosed under Item 404(a) of Regulation S-K.
In connection with Dr. Kennedy's appointment, Dr. Nicholas Vahanian resigned from his position as Chief Medical Officer of the Company. Dr. Vahanian will continue to serve the Company in his role as President.
On November 14, 2017, the Company issued a press release announcing the Company’s appointment of Dr. Kennedy as Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section9 – Financial Statements and Exhibits
Item 9.01.FinancialStatements and Exhibits.
Press Release, dated November 14, 2017, entitled “NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer”
NEWLINK GENETICS CORP ExhibitEX-99.1 2 nlnk-20171114x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1NewLink Genetics Appoints Eugene Kennedy,…To view the full exhibit click
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.